28.84

0.21% 0.06

After Hours: 28.15 -0.69 -2.39%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Beam Therapeutics Inc stock is traded at $28.84, with a volume of 1.99M. It is up +0.21% in the last 24 hours and up +17.62% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Previous Close:

$28.78

Open:

$28.72

24h Volume:

1.99M

Relative Volume:

1.01

Market Cap:

$2.98B

Revenue:

$164.01M

Net Income/Loss:

$-65.04M

P/E Ratio:

-41.98

EPS:

-0.687

Net Cash Flow:

$-383.84M

1W Performance:

+17.43%

1M Performance:

+17.62%

6M Performance:

-1.84%

1Y Performance:

+16.43%

1-Day Range:

$28.40

$29.76

1-Week Range:

$23.24

$29.76

52-Week Range:

$20.23

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (595)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

511

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	28.84	2.98B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	540.00	136.87B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	222.76	88.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	818.77	84.30B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	897.85	56.46B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.56	42.03B	5.76B	514.49M	1.10B	4.4813

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Canaccord Genuity	Buy
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

03:50 AM

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last? - Zacks Investment Research

03:50 AM

Oct 17, 2026

Beam Therapeutics CEO John Evans sells $1.19m in company stock By Investing.com - Investing.com South Africa

Oct 17, 2026

Oct 16, 2026

Beam Therapeutics CEO John Evans sells $1.19m in company stock - Investing.com

Oct 16, 2026

Form 4 Beam Therapeutics Inc: John M. Evans (Director, CEO) For: 15 October - Investing.com Nigeria

Oct 16, 2026

After $1.03 option exercises, Beam Therapeutics (BEAM) CEO sells 50,000 shares under a trading plan. - Stock Titan

Oct 16, 2026

After a $589K sale, John M. Evans proposes selling 25,000 Beam Therapeutics (BEAM) shares. - Stock Titan

Oct 16, 2026

Oct 15, 2026

A 25,000-share sale is planned by Beam Therapeutics (BEAM) officer and director John M. Evans. - Stock Titan

Oct 15, 2026

Oct 02, 2026

Beam Therapeutics SVP Bethany Cavanagh Sells 187 Shares to Cover RSU Tax Withholding - Kalkine Media

Oct 02, 2026

To cover taxes, Beam Therapeutics (BEAM) treasurer sells 187 shares automatically. - Stock Titan

Oct 02, 2026

Sep 29, 2026

Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca

Sep 29, 2026

Sep 25, 2026

Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly. - Stock Titan

Sep 25, 2026

Sep 22, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool

Sep 22, 2026

Sep 12, 2026

Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM) - webull.com

Sep 12, 2026

Sep 11, 2026

Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha

Sep 11, 2026

Sep 10, 2026

Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang

Sep 10, 2026

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance

Sep 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire

Sep 10, 2026